Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (71-80 of 154) with videos related to

Pageof 16
Sort By:
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
Clinical Genitourinary Cancer|September 23, 2014
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancerKevin F Kuo, Rachel Hunter-Merrill, Roman Gulati, et al.
The Prostate|July 11, 2018
Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survivalDaniel M Lim, Roman Gulati, Serge Aleshin-Guendel, et al.
Journal of the National Cancer Institute|February 19, 2020
Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate CancerEveline A M Heijnsdijk, Roman Gulati, Alex Tsodikov, et al.
Cancer Causes & Control : CCC|April 11, 2012
The impact of PLCO control arm contamination on perceived PSA screening efficacyRoman Gulati, Alex Tsodikov, Elisabeth M Wever, et al.
Anti-Cancer Drugs|February 5, 2010
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cellsColm Morrissey, Byron Gallis, Jeffrey W Solazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu, Roman Gulati, Donatello Telesca, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerGalina Semenova, Sander Frank, Ruth Dumpit, et al.
Cancer Causes & Control : CCC|November 21, 2007
Quantifying the role of PSA screening in the US prostate cancer mortality declineRuth Etzioni, Alex Tsodikov, Angela Mariotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu, Kevin F Kuo, Roman Gulati, et al.
Pageof 16

Showing results (71-80 of 154) with videos related to

Sort By:
Pageof 16
American Journal of Epidemiology|July 2, 2013
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, et al.
Clinical Genitourinary Cancer|September 23, 2014
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancerKevin F Kuo, Rachel Hunter-Merrill, Roman Gulati, et al.
The Prostate|July 11, 2018
Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survivalDaniel M Lim, Roman Gulati, Serge Aleshin-Guendel, et al.
Journal of the National Cancer Institute|February 19, 2020
Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate CancerEveline A M Heijnsdijk, Roman Gulati, Alex Tsodikov, et al.
Cancer Causes & Control : CCC|April 11, 2012
The impact of PLCO control arm contamination on perceived PSA screening efficacyRoman Gulati, Alex Tsodikov, Elisabeth M Wever, et al.
Anti-Cancer Drugs|February 5, 2010
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cellsColm Morrissey, Byron Gallis, Jeffrey W Solazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu, Roman Gulati, Donatello Telesca, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerGalina Semenova, Sander Frank, Ruth Dumpit, et al.
Cancer Causes & Control : CCC|November 21, 2007
Quantifying the role of PSA screening in the US prostate cancer mortality declineRuth Etzioni, Alex Tsodikov, Angela Mariotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu, Kevin F Kuo, Roman Gulati, et al.
Pageof 16